Serum	B-Organism_substance
and	O
urine	B-Organism_substance
levels	O
of	O
interleukin	O
-	O
8	O
in	O
patients	O
with	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	I-Cancer
.	O

Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
many	O
types	O
of	O
cancer	B-Cancer
.	O

Interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
is	O
known	O
to	O
be	O
a	O
pro	O
-	O
inflammatory	O
and	O
pro	O
-	O
angiogenic	O
cytokine	O
,	O
and	O
IL	O
-	O
8	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
tumor	B-Cancer
progression	O
,	O
prognosis	O
and	O
survival	O
in	O
several	O
types	O
of	O
cancers	B-Cancer
.	O

However	O
,	O
the	O
role	O
of	O
IL	O
-	O
8	O
in	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	I-Cancer
(	O
NHL	B-Cancer
)	O
has	O
not	O
been	O
fully	O
determined	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
usefulness	O
of	O
measuring	O
serum	B-Organism_substance
and	O
urine	B-Organism_substance
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	B-Cancer
.	O

We	O
developed	O
reference	O
intervals	O
for	O
serum	B-Organism_substance
and	O
urine	B-Organism_substance
IL	O
-	O
8	O
level	O
in	O
131	O
control	O
individuals	O
.	O

We	O
measured	O
serum	B-Organism_substance
IL	O
-	O
8	O
and	O
urine	B-Organism_substance
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	B-Cancer
,	O
and	O
we	O
compared	O
the	O
concentrations	O
with	O
those	O
of	O
control	O
individuals	O
.	O

The	O
reference	O
intervals	O
for	O
serum	B-Organism_substance
IL	O
-	O
8	O
and	O
urine	B-Organism_substance
IL	O
-	O
8	O
corrected	O
by	O
creatinine	O
(	O
Cr	O
)	O
were	O
15	O
.	O
9	O
-	O
430	O
.	O
3	O
pg	O
/	O
mL	O
and	O
0	O
.	O
0	O
-	O
28	O
.	O
4	O
pg	O
/	O
mg	O
Cr	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
urine	B-Organism_substance
IL	O
-	O
8	O
/	O
Cr	O
were	O
significantly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
48	O
.	O
9	O
+	O
/	O
-	O
194	O
.	O
4	O
vs	O
.	O
5	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
8	O
pg	O
/	O
mg	O
Cr	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
serum	B-Organism_substance
IL	O
-	O
8	O
concentrations	O
between	O
NHL	B-Cancer
patients	O
and	O
controls	O
(	O
159	O
.	O
2	O
+	O
/	O
-	O
40	O
.	O
4	O
vs	O
.	O
99	O
.	O
6	O
+	O
/	O
-	O
107	O
.	O
1	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
099	O
)	O
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
gave	O
0	O
.	O
83	O
and	O
0	O
.	O
43	O
ROC	O
area	O
values	O
for	O
urine	B-Organism_substance
IL	O
-	O
8	O
/	O
Cr	O
and	O
serum	B-Organism_substance
IL	O
-	O
8	O
,	O
respectively	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
serum	B-Organism_substance
and	O
urine	B-Organism_substance
concentrations	O
of	O
IL	O
-	O
8	O
and	O
clinical	O
variables	O
,	O
the	O
only	O
exception	O
being	O
the	O
international	O
prognostic	O
index	O
(	O
IPI	O
)	O
,	O
which	O
showed	O
a	O
marginal	O
correlation	O
with	O
urine	B-Organism_substance
IL	O
-	O
8	O
/	O
Cr	O
levels	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

This	O
study	O
indicated	O
that	O
urine	B-Organism_substance
IL	O
-	O
8	O
/	O
Cr	O
levels	O
might	O
be	O
useful	O
as	O
a	O
diagnostic	O
marker	O
of	O
NHL	B-Cancer
.	O

